5-(2-甲基-2-丙基)-1,3-苯并恶唑 | 908011-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 中文名称: 5-(2-甲基-2-丙基)-1,3-苯并恶唑
• 中文别名: 5-叔丁基苯并噁唑
• 英文名称: 5-tert-butylbenzo[d]oxazole
• 英文别名: 5-tert-butylbenzoxazole；5-(tert-Butyl)benzoxazole；5-tert-butyl-1,3-benzoxazole
• CAS: 908011-92-7
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: MXJGWNPVKBVVTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(2-甲基-2-丙基)-1,3-苯并恶唑 在 2,3,4,5,6-五氟碘苯 、 potassium tert-butylate 作用下， 以 甲苯 为溶剂， 以80 %的产率得到5-(tert-butyl)-2-iodobenzo[d]oxazole
  参考文献：
  名称：

  Copper‐Catalyzed Aryne Insertion into the Carbon‐Iodine Bond of Heteroaryl Iodides

  摘要：

  摘要 首次实现了在杂芳基碘化物的碳-碘键中插入丙烯。这一新型反应为从杂芳基碘化物和邻硅芳基三酸酯合成有价值的 2-iodoheterobiaryls 构建模块提供了一条高效途径，且具有极佳的区域选择性。铜（I）催化剂带有 N-杂环碳烯（NHC）配体，对完成反应至关重要。对照反应和 DFT 计算表明，作为路易斯酸的铜与杂芳基碘化物的氮原子配位介导了芳基插入杂芳基碳-碘键。

  DOI：

  10.1002/anie.202305146
• 作为产物：
  描述：

  原甲酸三乙酯 、 2-氨基-4-叔丁基酚 以100%的产率得到5-(2-甲基-2-丙基)-1,3-苯并恶唑
  参考文献：
  名称：

  铜催化苯并恶唑与2-硝基苯甲酸的氧化脱羧CH芳基化

  摘要：

  建立了铜催化的苯并恶唑与2-硝基苯甲酸的氧化脱羧偶联反应。这种方法学偏爱富含电子的苯并恶唑和缺乏电子的苯甲酸，并能够制备各种芳基化的...

  DOI：

  10.1039/c5cc06645j

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Asana Biosciences, LLC

  公开号：US20160362407A1

  公开（公告）日：2016-12-15

  The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R 1 to R 8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的杂环化合物及其药用可接受的盐。还提供了制备这些化合物的方法。这些化合物对抑制ERK1/2有用。通过向需要治疗的患者施用式(I)的一个或多个化合物的治疗有效量，其中X、Y、Z、J、M和R1至R8在此处定义，这些化合物在治疗与RAS/RAF/MEK/ERK通路失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190224188A1

  公开（公告）日：2019-07-25

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式(I)的化合物及其药学上可接受的盐： 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Copper-Catalyzed Oxidative Amination of Benzoxazoles via C−H and C−N Bond Activation: A New Strategy for Using Tertiary Amines as Nitrogen Group Sources
  作者：Shengmei Guo、Bo Qian、Yinjun Xie、Chungu Xia、Hanmin Huang

  DOI：10.1021/ol1030298

  日期：2011.2.4

  method for oxidative amination of azoles with tertiary amines via copper-catalyzed C−H and C−N bond activation has been developed. This protocol can be performed in the absence of external base and only requires atmospheric oxygen as oxidant. The catalyst system is very simple and efficient, which opens a new way for using tertiary amines as nitrogen group sources for C−N bond formation reactions.

  通过铜催化的CH和CN键活化作用，开发了一种高效，概念上新颖的用叔胺氧化唑类胺的方法。该方案可以在不存在外部碱的情况下进行，并且仅需要大气中的氧气作为氧化剂。催化剂体系非常简单和高效，这为使用叔胺作为C-N键形成反应的氮源提供了新途径。